Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Keryx Biopharmaceuticals Inc

+ Add to Watchlist

KERX:US

10.3300 USD 0.3300 3.10%

As of 20:10:00 ET on 05/22/2015.

Company Profile for Keryx Biopharmaceuticals Inc (KERX)

Keryx Biopharmaceuticals, Inc. is focused on developing and commercializing pharmaceuticals for the treatment of renal disease. The Company's product candidate completed Phase 3 testing, pursuant to an SPA agreement with the FDA, for hyperphosphatemia in ESRD patients. The product candidate is also in Phase 2 for non-dialysis dependent CKD patients with iron-deficiency anemia.

Contact Information

Keryx Biopharmaceuticals Inc

750 Lexington Avenue
New York, NY 10022
United States
Phone: 1-212-531-5965
Fax: 1-212-531-5961

Key Executives for Keryx Biopharmaceuticals Inc (KERX)

Gregory P Madison "Greg"President/COOJames F OlivieroCFO/Treasurer/Secretary
John F NeylanChief Medical OfficerBrian R AdamsVP/General Counsel
Lauren FischerDirector:Investor Relations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil